Dear Reader,

As you may have heard, we’ll soon be launching a new letter focused on the latest longevity, bio enhancers, and biotech investment recommendations.

There are well-researched new therapies that may stave off early-stage dementia and Alzheimer’s, increase your ability to build muscle mass, getter better sleep, and keep you running longer.

In fact, one genetics professor now says the first person to live to age 150 has already been born.

Dr. Mike Roizen, Cleveland Clinic’s founding wellness chair and friend of Mauldin Economics, says we can make the actual age of our body about 30 years younger now. So, at calendar age 90, you can function as if 60. And soon, maybe much younger—likely being able to function as if 40 at age 90.

In short, longevity and biotech are entering a golden age. That’s why we’re excited to launch a new letter that will shine a spotlight on the latest breakthroughs.

Chris Wood will be leading this effort along with our old friend Patrick Cox.

To kick things off, Chris has just put together a free special report on the “Three Buckets of Biotech Profits.” Inside he discusses the three big buckets of longevity-related stocks you should target to strike the right balance of upside and risk management.

To get the free special report, additional bonuses, and all the updates on this coming letter, sign up here.

We hope you find it interesting and insightful.

Best Regards,

Mauldin Economics

TLDR: Mauldin Economics is launching a new letter focused on the latest longevity and biotech investing recommendations. To kick things off, Chris Wood has just put together a free special report on the “Three Buckets of Biotech Profits.” Sign up here, to download it for free.